Physician profile
Nabil Rizk
NPI 1578549168
$3,984.96
in general payments reported to CMS, 2019-2025
10 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $16.06 · 2022: $2,315 · 2023: $131 · 2024: $82.06 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,426.95 | 2019-2022 | |
| Davol INC. | $202.87 | 2023-2025 | Channel Drain, Phasix Mesh |
| Atricure, INC. | $104.28 | 2023-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Medtronic, INC. | $85.04 | 2022-2024 | Signia |
| Astrazeneca Pharmaceuticals LP | $50.54 | 2022-2025 | Tagrisso, Imfinzi |
| Guard Medical INC. | $38.76 | 2025 | Npseal |
| Olympus America INC. | $23.04 | 2024 | Visera Elite II Video System Center |
| Becton, Dickinson and Company | $20.80 | 2024 | Channel Drain |
| Kerecis Limited | $16.62 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Covidien LP | $16.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Rizk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.